| Today's Big NewsMay 5, 2023 |
| By James Waldron In what looks set to be one of the biggest biotech IPOs of the year, Acelyrin has revealed that it’s expecting to raise $540 million to push its immune drug candidates through the clinic. |
|
|
|
By Nick Paul Taylor AstraZeneca is rowing back from its bet on oncolytic viruses. Four years after stepping up its presence in the immuno-oncology field through a five-asset pact with Transgene, the Anglo-Swedish drug developer has scrapped the partnership before moving a candidate into the clinic. |
By James Waldron An analyst has reiterated that Selecta’s portfolio is “promising” despite the biotech offloading a quarter of its workforce along with non-partnered gene therapy programs. |
By Annalee Armstrong Boehringer Ingelheim is heading out into the surf with Australia's Kinoxis Therapeutics in a $181 million biobucks deal to develop therapies for neuropsychiatric disorders. |
By Nick Paul Taylor Cellectis has given up on its multiple myeloma CAR-T candidate UCARTCS1. With the phase 1 clinical trial two years behind schedule and heavy investment needed to accelerate enrollment, the off-the-shelf cell therapy specialist is stopping the study and focusing its resources on three other candidates. |
By Gabrielle Masson,Max Bayer Cerevel CEO Tony Coles, M.D., will be handing over the reins to Bain Capital’s Ron Renaud on June 12. |
By Teresa Carey This week on "The Top Line," we're continuing our miniseries on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription. |
By Andrea Park Already under fire for other aspects of its animal testing program, Neuralink is in the hot seat once again, this time for a Reuters report on potential conflicts of interest tied to the oversight board governing the animal research program. |
By Paige Minemyer The Cigna Group rounded out earnings for the large national insurers on Friday morning, where it reported $1.3 billion in profit for the first quarter of 2023. |
By Kevin Dunleavy Six months after Gilead got a smackdown in the U.S. for its drug to treat hepatitis delta virus, bulevirtide has scored a regulatory win in Europe. The Committee for Medicinal Products for Human Use (CHMP) has given bulevirtide a thumbs up for patients with HDV and compensated liver disease. |
By Andrea Park Just a few months after it began pruning back operations at a trio of its test-making facilities in San Diego, Thermo Fisher Scientific is now completely uprooting all three. |
By Angus Liu Astellas paid $5.9 billion to join the complement inhibitor battle in geographic atrophy. J&J put down $245 million upfront to partner with a CAR-T biotech with operations in China and the U.S. Sun Pharma's JAK inhibitor hit a partial clinical hold in alopecia. And more. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we're continuing our miniseries on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription. |
|
|---|
|
|
|
July 18-19, 2023 | Jersey City, NJ
Connect with senior PR and communications leaders from big pharma, small-mid size pharma, biotech and more to gain insights and best practices on daily challenges in the industry. Save $500 when you Register Today! 
|
|
eBook Discover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
Whitepaper This paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Research Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
Whitepaper For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
